Additionally, other studies by Camino et al confirmed that FABP4 is an AdEV-specific obesity marker and that both mimecan and transforming growth factor beta induced (TGFBI) are biomarkers for obesity comorbidities. Here, TGFBI is linked to obesity disorder.